Maternal and Microbiological Outcomes in GBS-Positive Patients Receiving Intrapartum Ampicillin versus Clindamycin: A Retrospective Cohort Study
Gynecologic and Obstetric Investigation · 2025
DOI: 10.1159/000549302 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Gynecologic and Obstetric Investigation, 2025. Verfasst von Raneen Abu Shqara und 5 weiteren Autor:innen. Beteiligte Einrichtung: Raya Strauss Wing of Obstetrics and Gynecology, Galilee Medical Center, Nahariya, Israel, rabushqara@gmail.com. Hauptthemen laut MEDLINE: Clindamycin, Ampicillin, Streptococcal Infections, Anti-Bacterial Agents. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
Early-onset Group B Streptococcus (GBS) infection is a major cause of neonatal morbidity and mortality, which can be prevented through intrapartum antibiotic prophylaxis (IAP). First-line β-lactams (penicillin or ampicillin) are preferred, whereas clindamycin is reserved for patients with a confirmed high-risk penicillin allergy and documented susceptibility. Increasing clindamycin resistance and concerns about intra-amniotic efficacy highlight the need to evaluate maternal outcomes. This study examined maternal infectious morbidity, neonatal outcomes, and microbiological findings in GBS-positive term patients receiving ampicillin versus clindamycin IAP.
Design
This retrospective cohort study was conducted between March 2021 and March 2024 at a tertiary university-affiliated hospital. Participants/Materials: Singleton term pregnancies (≥37 weeks) with a documented positive GBS vaginal-rectal culture obtained within 5 weeks before delivery were included. Patients received either ampicillin (n = 1,833) according to the institutional protocol or clindamycin (n = 78) if they reported a severe β-lactam allergy. No intrapartum clindamycin susceptibility testing was performed.
Setting
The study was conducted at a tertiary university-affiliated hospital between March 2021 and March 2024.
Methods
The co-primary outcomes were clinical chorioamnionitis and admission to the neonatal intensive care unit (NICU). Secondary maternal outcomes included intrapartum fever, postpartum fever, postpartum antibiotic administration use, and cesarean delivery. Secondary neonatal outcomes included a 5-min Apgar score of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Raya Strauss Wing of Obstetrics and Gynecology, Galilee Medical Center, Nahariya, Israel, rabushqara@gmail.com.
- Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel, rabushqara@gmail.com.
- Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
- Raya Strauss Wing of Obstetrics and Gynecology, Galilee Medical Center, Nahariya, Israel.
Zitieren
APA
Abu Shqara, R., Or, S., Goldinfeld, G., Ganem, N., Lowenstein, L., & Frank Wolf, M. (2025). Maternal and Microbiological Outcomes in GBS-Positive Patients Receiving Intrapartum Ampicillin versus Clindamycin: A Retrospective Cohort Study. Gynecologic and Obstetric Investigation. https://doi.org/10.1159/000549302
Vancouver
Abu Shqara R, Or S, Goldinfeld G, Ganem N, Lowenstein L, Frank Wolf M. Maternal and Microbiological Outcomes in GBS-Positive Patients Receiving Intrapartum Ampicillin versus Clindamycin: A Retrospective Cohort Study. Gynecologic and Obstetric Investigation. 2025. doi:10.1159/000549302
BibTeX
@article{AbuShqara2025,
author = {Abu Shqara, Raneen and Or, Shany and Goldinfeld, Gabriela and Ganem, Nadir and Lowenstein, Lior and Frank Wolf, Maya},
title = {Maternal and Microbiological Outcomes in GBS-Positive Patients Receiving Intrapartum Ampicillin versus Clindamycin: A Retrospective Cohort Study},
journal = {Gynecologic and Obstetric Investigation},
year = {2025},
doi = {10.1159/000549302}
}
EUVIMED